WP
TRDA icon

Woodline Partners’s Entrada Therapeutics TRDA Stock Holding History

Woodline Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Sell
145,600
-70,377
-33% -$675K ﹤0.01% 908
2026
Q1 		$2.73M Buy
215,977
+73,867
+52% +$847K 0.01% 768
2025
Q4 		$1.46M Buy
+142,110
New +$1.2M 0.01% 809

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Woodline Partners's TRDA Position: Q2 2026 in Review

Woodline Partners reduced its Entrada Therapeutics (TRDA) stake by 33% in Q2 2026, selling an estimated $675K and leaving 145,600 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #908.

Woodline Partners first reported a position in TRDA in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.73M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Woodline Partners held 145,600 shares of Entrada Therapeutics worth $1.07M as of Q2 2026.
  • Woodline Partners sold 70,377 Entrada Therapeutics shares in Q2 2026, an estimated $675K.
  • Entrada Therapeutics made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #908 holding.
  • Woodline Partners first reported a position in Entrada Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Woodline Partners's Entrada Therapeutics position peaked at $2.73M in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.